Why the study?
Does intrapericardial instillation of cisplatin prevent reaccumulation of pericardial fluid in a patient with malignant pericardial effusion?
Does intrapericardial instillation of cisplatin prevent reaccumulation of pericardial fluid in a patient with malignant pericardial effusion?
Intrapericardial instillation of cisplatin successfully controlled malignant pericardial effusion in a single patient without side effects, suggesting a potential therapeutic option warranting further investigation.
Answers are grounded in this paper and cite their sources.
May control malignant effusion without toxicity in select cases; leaves open prospective validation before clinical use.
Cisplatin (10 mg in 50 ml normal saline) was administered daily for five days directly into the pericardial cavity of a patient with metastatic nonsmall cell lung cancer and a malignant pericardial effusion. No systemic or local side effects were observed. A dramatic decrease in reaccumulation of pericardial fluid was noted which persisted until the patient's death four months later. On the basis of this experience, further investigation of the intrapericardial administration of cisplatin as treatment to control malignant pericardial effusions appears warranted.
No takes yet. Share an insight, caveat, or question.
Markman et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: